Replimune Group, Inc. announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company's upcoming annual general meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.41 USD | -4.75% | -7.77% | -23.96% |
Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
Mar. 26 | Replimune Group, Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.96% | 393M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors